Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 24;16:3023–3034. doi: 10.2147/CCID.S430852

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Liu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Axitinib significantly reduced levels of p-AKT, p70S6K and p-p70S6K shown in Western blot results. (A) The protein levels of AKT and p-AKT, p70S6K and p-p70S6K were determined by immunoblot (n = 6 per group). (B) No significant difference in the relative levels of AKT was detected (P > 0.05). (C–E) The relative levels of p-AKT (C), p70S6K (D) and p-p70S6K (E) in the axitinib group were significantly lower than that in the control group (P < 0.05). *P < 0.05.